RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Stopped early · Phase 2

Conditions studied: Myelodysplastic Syndromes

In brief

RATIONALE: RAD001(Everolimus) may stop the growth of cancer cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well RAD001(everolimus) works in treating patients with myelodysplastic syndromes.

Key facts

Study ID

NCT00809185

Run by

Case Comprehensive Cancer Center

People needed

7

Starts

2005-11-01

Expected to finish

2009-03-01

Last updated by the study team

2019-03-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.